Integer Holdings Corp (ITGR) · Oct 29, 2026 · Earnings
Miss — Adjusted EPS $1.34 vs ~$1.68 consensus; revenue $449.7M vs ~$456.9M
Integer’s Q3 earnings missed on revenue and adjusted EPS, with falling cardio sales and weaker margins overshadowing growth in rhythm management.
Integer is a medical-device CDMO trying to shift growth toward cardiac rhythm management and neuromodulation while absorbing weakness in cardio and vascular and exiting Portable Medical. The pending KKR acquisition also means management has suspended outlook and conference-call commentary, so this quarter is mainly a read on the underlying operating trend rather than a new forecast.
This was a clear quarterly miss, not merely a noisy comparison. Published Q3 expectations were roughly $456.9 million of revenue and $1.68 of adjusted EPS; Integer delivered $449.7 million and $1.34, respectively.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Sales (Summary Financial Results) | $449.7M (-3.9%) | $467.7M | ~$456.9M |
| Adjusted operating income (Summary Financial Results) | $66.3M (-22.8%) | $85.9M | |
| Adjusted EBITDA (Summary Financial Results) | $87.9M (-17.0%) | $105.9M | |
| Adjusted EPS (Summary Financial Results) | $1.34 (-25.1%) | $1.79 | ~$1.68 |
| Net total debt (Net Total Debt Reconciliation) | $1.223B | $1.190B |
The core problem is weaker demand and conversion, not just the Portable Medical exit. Sales decreased 3.9% to $450million. Cardio & Vascular fell 5.1%, while the healthier Cardiac Rhythm Management & Neuromodulation business grew 3.9%; that growth was not enough to offset the larger cardio franchise and the strategic exit from Other Markets.
Profitability deteriorated faster than sales. Adjusted operating income fell 22.8% and adjusted EBITDA fell 17.0%, implying a substantial margin squeeze as volume weakened and Integer continued to absorb restructuring, ERP implementation, legal, transaction, and other adjustment costs. The GAAP picture was much worse—operating income fell 50%—but the adjusted decline still shows the underlying business did not hold up well.
The result is partly known, but the magnitude is new. Integer had already lowered its 2026 outlook before this release and is withholding new guidance because of the KKR transaction, so slower growth was not a surprise. But the revenue shortfall, 25% adjusted-EPS decline, and higher net debt reinforce that the standalone operating story remains under pressure rather than stabilizing.
The transaction now matters more than any near-term forecast. Stockholders approved the merger on October 21, and the company says closing is anticipated by year-end 2026, subject to remaining customary conditions and regulatory approvals. 〔0〕
Bottom line: Integer missed a lowered operating bar, with its growth segment unable to offset cardio weakness and margin pressure. The KKR deal limits the importance of future guidance, but this quarter still weakens the standalone business story before closing.
KKR transaction closing, targeted by year-end 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!